Trial · NCT00570531
Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma
NCT00570531, Phase 2, Terminated, University of Michigan Rogel Cancer Center; results first posted 2015-01-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma. Trials, record NCT00570531. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00570531
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma
- NCT number
- NCT00570531
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Conditions
- Loco-regional Esophageal Cancer
- Interventions
- Bevacizumab, Paclitaxel, Cisplatin, 5-Fluorouracil, Radiation Therapy, Esophagectomy
- First posted
- 2007-12-11
- Last updated
- 2016-05-26
- Results first posted
- 2015-01-12
- Limitations and caveats
- The study was unable the accrue the required number of patients within a reasonable time and therefore the primary objective was not analyzed.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease Free Survival Time | 5 years | The primary outcome that will be measured is the length of time that patients are alive without recurrence of cancer following this therapy. |
| Secondary | The Number of Patients Cancer Free at the Time of Surgery | 1 year | Determination of whether the pre-operative treatment can eliminate all the cancer cells at the time of surgery. |
| Secondary | The Proportion of Toxicities Experienced by Participants | Every three weeks for one year | To assess the toxicity of this regimen. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Disease Free Survival Time | 5 years | The study was unable to accrue the number of patients necessary to analyze the primary objective. | ||
| SECONDARY | The Number of Patients Cancer Free at the Time of Surgery | 1 year | The study was unable to accrue the number of patients necessary to analyze the objective. | ||
| SECONDARY | The Proportion of Toxicities Experienced by Participants | Every three weeks for one year | The study was unable to accrue the number of patients necessary to analyze the objective. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bevacizumab | 6 | |
| Overall Study | COMPLETED | Bevacizumab | 6 | |
| Overall Study | NOT COMPLETED | Bevacizumab | 0 |
Source ClinicalTrials.gov
Adverse events110
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Allergic Rhinitis | Immune system disorders | Bevacizumab | 1 | 6 | 1 |
| other | Hemoglobin | Blood and lymphatic system disorders | Bevacizumab | 4 | 6 | 11 |
| other | Leukocytes (total WBC) | Blood and lymphatic system disorders | Bevacizumab | 1 | 6 | 4 |
| other | Lymphopenia | Blood and lymphatic system disorders | Bevacizumab | 2 | 6 | 6 |
| other | Neutrophils/granulocytes (ANC/AGC) | Blood and lymphatic system disorders | Bevacizumab | 2 | 6 | 2 |
| other | Platelets | Blood and lymphatic system disorders | Bevacizumab | 1 | 6 | 1 |
| other | Prolonged QTc interval | Cardiac disorders | Bevacizumab | 1 | 6 | 1 |
| other | Atrial fibrillation | Cardiac disorders | Bevacizumab | 1 | 6 | 4 |
| other | Atrial flutter | Cardiac disorders | Bevacizumab | 2 | 6 | 2 |
| other | Sinus bradycardia | Cardiac disorders | Bevacizumab | 1 | 6 | 1 |
1 to 10 of 110Source ClinicalTrials.gov
See all 110 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bevacizumab | ||
| Total, other adverse events | Bevacizumab | 6 | 6 |
| Total, serious adverse events | Bevacizumab | 4 | 6 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00570531
GET https://conductscience.org/api/trials/v1/NCT00570531/events?page=2